Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 440

1.

Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation.

Schroeder EB, Yang X, Thorp ML, Arnold BM, Tabano DC, Petrik AF, Smith DH, Platt RW, Johnson ES.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):87-94. doi: 10.2215/CJN.01290216.

PMID:
28028051
2.

The Kidney in Hypertension.

Sternlicht H, Bakris GL.

Med Clin North Am. 2017 Jan;101(1):207-217. doi: 10.1016/j.mcna.2016.08.001. Review.

PMID:
27884230
3.

BR 04-1MANAGEMENT OF TREATMENT-RESISTANT HYPERTENSION.

Webb DJ.

J Hypertens. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e198.

PMID:
27754015
4.

[Adrenomedullin in the kidney: physiology and pathophysiology].

Sogbe-Díaz ME, Díaz-López EE.

Invest Clin. 2016 Mar;57(1):66-76. Review. Spanish.

PMID:
27382803
5.

Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

Ahmed A, Jorna T, Bhandari S.

Nephron. 2016;133(3):147-58. doi: 10.1159/000447068.

6.

Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A.

Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3. Review.

PMID:
26559744
7.

BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.

Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, Guarino P, Fried LF; VA NEPHRON-D Study Group..

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2159-69. doi: 10.2215/CJN.02850315.

8.

[Renal hypertension--the role of the kidneys in blood pressure regulation and the kidneys as end organ].

Grendelmeier I.

Ther Umsch. 2015 Jun;72(6):369-74. doi: 10.1024/0040-5930/a000688. Review. German.

PMID:
26098186
9.

Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative.

De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, Russo G, Rossi MC, Nicolucci A, Guida P, Di Bartolo P, Pontremoli R; AMD-Annals Study Group..

Nephrol Dial Transplant. 2015 Sep;30(9):1526-33. doi: 10.1093/ndt/gfv101.

PMID:
25883195
10.

Is peritoneal dialysis still an equal option? Results of the Berlin pediatric nocturnal dialysis program.

Thumfart J, Hilliger T, Stiny C, Wagner S, Querfeld U, Müller D.

Pediatr Nephrol. 2015 Jul;30(7):1181-7. doi: 10.1007/s00467-015-3043-4.

PMID:
25877914
11.

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

Schievink B, de Zeeuw D, Parving HH, Rossing P, Lambers Heerspink HJ.

Br J Clin Pharmacol. 2015 Oct;80(4):678-86. doi: 10.1111/bcp.12655.

12.

Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.

Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL.

Am J Nephrol. 2014;40(6):572-81. doi: 10.1159/000371497.

PMID:
25591469
13.

Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.

Chrysant SG, Chrysant GS.

Curr Hypertens Rep. 2015 Jan;17(1):511. doi: 10.1007/s11906-014-0511-3. Review.

PMID:
25447989
14.

Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.

McGovern AP, Jones S, van Vlymen J, Saggar AK, Sandford R, de Lusignan S.

BMC Nephrol. 2014 Nov 20;15:182. doi: 10.1186/1471-2369-15-182.

15.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators..

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686.

16.

Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.

Yilmaz MI, Sonmez A, Saglam M, Kurt YG, Unal HU, Karaman M, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Vural A, Mallamaci F, Zoccali C.

Am J Nephrol. 2014;40(3):208-14. doi: 10.1159/000366169.

17.

High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients.

Nerbass FB, Pecoits-Filho R, McIntyre NJ, McIntyre CW, Taal MW.

Eur J Clin Nutr. 2015 Jul;69(7):786-90. doi: 10.1038/ejcn.2014.215.

PMID:
25293433
18.

Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).

Uchida S, Takahashi M, Sugawara M, Saito T, Nakai K, Fujita M, Mochizuki K, Shin I, Morita T, Hikita T, Itakura H, Takahashi Y, Mizuno S, Ohno Y, Ito K, Ito T, Soma M.

J Clin Hypertens (Greenwich). 2014 Oct;16(10):746-53. doi: 10.1111/jch.12412.

19.

Management of proteinuria in the transplanted patient.

Seeman T.

Pediatr Nephrol. 2015 Jun;30(6):889-903. doi: 10.1007/s00467-014-2876-6. Review.

PMID:
25159718
20.

Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.

Kovesdy CP, Lu JL, Molnar MZ, Ma JZ, Canada RB, Streja E, Kalantar-Zadeh K, Bleyer AJ.

JAMA Intern Med. 2014 Sep;174(9):1442-9. doi: 10.1001/jamainternmed.2014.3279. Erratum in: JAMA Intern Med. 2014 Oct;174(10):1709.

Items per page

Supplemental Content

Loading ...
Support Center